Exhaled Nitric Oxide is Not a Biomarker for Pulmonary Tuberculosis
Authors:
- José W. LópezJLJosé W. López
- Maria-Cristina I. LoaderMLMaria-Cristina I. Loader
- Daniel SmithDSDaniel Smith
- Daniel PastoriusDPDaniel Pastorius
- Marjory BravardMBMarjory Bravard
- Karina M. RomeroKRKarina M. Romero
- Taryn ClarkTCTaryn Clark
- William CheckleyWCWilliam Checkley
- Eduardo TiconaETEduardo Ticona
- Jon S. FriedlandJFJon S. Friedland
- Robert H. GilmanRGRobert H. Gilman
Open Access
- 6 June 2018
- journal article
- research article
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 98 (6) , 1637-1639
Abstract
To reduce transmission of tuberculosis (TB) in resource-limited countries where TB remains a major cause of mortality, novel diagnostic tools are urgently needed. We evaluated the fractional concentration of exhaled nitric oxide (FeNO) as an easily measured, noninvasive potential biomarker for diagnosis and monitoring of treatment response in participants with pulmonary TB including multidrug resistant–TB in Lima, Peru. In a longitudinal study however, we found no differences in baseline median FeNO levels between 38 TB participants and 93 age-matched controls (13 parts per billion [ppb] [interquartile range (IQR) = 8–26] versus 15 ppb [IQR = 12–24]), and there was no change over 60 days of treatment (15 ppb [IQR = 10–19] at day 60). Taking this and previous evidence together, we conclude FeNO is not of value in either the diagnosis of pulmonary TB or as a marker of treatment response.Keywords
This publication has 17 references indexed in Scilit:
- Measurement of levels of fractional exhaled nitric oxide in patients with pulmonary tuberculosisThe International Journal of Tuberculosis and Lung Disease, 2016
- Longitudinal Assessment of High Versus Low Levels of Fractional Exhaled Nitric Oxide Among Children with Asthma and AtopyLung, 2014
- Impaired Pulmonary Nitric Oxide Bioavailability in Pulmonary Tuberculosis: Association With Disease Severity and Delayed Mycobacterial Clearance With TreatmentThe Journal of Infectious Diseases, 2013
- An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (F e NO) for Clinical ApplicationsAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Tuberculosis into the 2010s: Is the Glass Half Full?Clinical Infectious Diseases, 2009
- The Use of Fraction of Exhaled Nitric Oxide in Pulmonary PracticeChest, 2008
- Microscopic-Observation Drug-Susceptibility Assay for the Diagnosis of TBNew England Journal of Medicine, 2006
- Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosisEuropean Respiratory Journal, 2003
- What is the Role of Nitric Oxide in Murine and Human Host Defense against Tuberculosis?American Journal of Respiratory Cell and Molecular Biology, 2001
- Early Inhibition of Mycobacterial Growth by Human Alveolar Macrophages is not Due to Nitric OxideAmerican Journal of Respiratory and Critical Care Medicine, 1998